- CVS Caremark study: More education needed on genetic testing in prescribing antiplatelet drugs
- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
- On the heels of Q3, Walgreens outlines shift in front-end strategy and pharmacy tailwinds looking forward
- NACDS, NCPA, GPhA express support for Drug Quality and Security Act
- FDA issues sweeping new requirements for long-acting opioids
MUMBAI, India — The Food and Drug Administration has approved a generic diabetes drug made by Sun Pharmaceutical Industries, Sun said Friday.
The Indian generic drug maker announced the approval of repaglinide tablets in the 1-mg and 2-mg strengths, which are used in combination with diet and exercise to improve blood-sugar control in patients with Type 2 diabetes.
The drug is a generic version of Novo Nordisk's Prandin, which has annual sales of about $200 million, according to Sun. Sun filed for approval with a Paragraph IV certification, a legal assertion that Prandin's patent protection is invalid, unenforceable or not in danger of infringement. As the first company to successfully file for approval, Sun is eligible for 180 days of market exclusivity in which to compete directly with Novo Nordisk's version.
Are you a nurse practitioner or physician's assistant? Join our Facebook group to get all the latest news dedicated to delivering healthcare services to patients in retail pharmacy clinics.